Double-blind controlled crossover high-dose study of Azaribine in psoriasis.

Abstract	Azaribine used in high doses of 200 mg/kg a day is an effective agent in inducing temporary remissions in patients with severe psoriasis but potentially serious neurotoxicity may occur. Therapy should be initiated at lower doses of 125 mg/kg a day and advanced carefully only if clinical response does not ensue at the lower level.
Authors	W A Crutcher, S L Moschella
Journal	The British journal of dermatology (Br J Dermatol) Vol. 92 Issue 2 Pg. 199-205 (Feb 1975) ISSN: 0007-0963 [Print] England
PMID	1096923 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Placebos Azauridine
Topics	Adult Azauridine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use) Brain Diseases (chemically induced) Clinical Trials as Topic Electroencephalography Female Humans Male Middle Aged Placebos Psoriasis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!